Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | FNTA | P49354 | 9/20 | 0.53 |
| ▸ | FNTB | P49356 | 9/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454748 | 0.89 | FNTA (0.60) | MEN1KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL15124140 | 0.88 | FNTA (0.65) | MEN1KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL1722397 | 0.78 | MEN1 (0.61) | MEN1KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL454305 | 0.77 | FNTA (0.88) | FNTAFNTBPGGT1B | |
| SCHEMBL455566 | 0.76 | LMNA (0.52) | MEN1KMT2ALMNA | |
| SCHEMBL1723248 | 0.73 | MEN1 (0.55) | MEN1KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL455264 | 0.73 | FNTA (0.80) | MEN1KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL1723280 | 0.71 | KMT2A (0.49) | MEN1KMT2AFNTAFNTBTAS2R14 | |
| SCHEMBL2212915 | 0.71 | MEN1 (0.58) | MEN1KMT2AFNTAFNTBPGGT1B | |
| SCHEMBL15124128 | 0.71 | LTA4H (0.40) | MEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040563-B2 | Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | YALE UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034038-A2 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190355-A1 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I | FNTA, FNTB, GDI1 | MEN1 2855/4885KMT2A 3248/4885FNTA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.